Damora Therapeutics Inc (NASDAQ:DMRA) saw its stock climb 15.5% on Monday after the company revealed a new chief executive and multiple additions to its board of directors. Jennifer Jarrett will take on the roles of President and Chief Executive Officer, with her appointment effective March 30, 2026.
Jarrett arrives with close to 30 years of senior leadership across biotech, technology and finance. Her most recent position was Chief Operating Officer at Arcus Biosciences, where she also served as Chief Financial Officer and was a member of the company’s board. Earlier in her career she was Chief Financial Officer at Medivation, a commercial oncology company that developed XTANDI (enzalutamide) for prostate cancer, remaining in that role through Medivation’s acquisition by Pfizer.
The company also announced new board members: Dr. Cameron Turtle, who is Chief Executive Officer of Spyre Therapeutics; and Mike Landsittel, the former Chief Financial Officer of Blueprint Medicines. In addition, Peter Harwin, a founding partner at Fairmount Funds Management, has been named Chairman of the Board.
Board leadership reaction
Commenting on the appointment, Harwin highlighted Jarrett’s record in oncology drug development and experience leading high-growth companies, saying that her strategic and operational background will be important as Damora aims to realize its potential.
Jarrett’s background also includes two decades in investment banking, including a tenure at Citigroup where she led the west coast life sciences investment banking practice. Her academic credentials listed by the company include a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business.
Company focus and recent corporate moves
Damora describes itself as a biotechnology company developing treatments for blood disorders. Its lead clinical candidate, DMR-001, targets mutant calreticulin-driven myeloproliferative neoplasm.
The announced governance changes follow a recent transaction with Galecto, and were accompanied by the departure of three directors: Dr. Carl Goldfischer, Dr. Jayson Dallas and Amit Munshi.
The market reaction on the day of the leadership update was a notable single-session rise in Damora’s share price. The company has positioned its new executive team and board to steer ongoing development of its lead program while managing the post-transaction governance transition.
What this means for investors and stakeholders
The leadership appointments represent a clear management transition at Damora and a reconstituted board intended to support the company’s clinical and corporate objectives. The board composition now includes executives with experience in oncology development, biotech finance and public company financial leadership.